Lupin Share Price

Pharma stocks: Nomura gives 'Buy' to Lupin remains 'Neutral' on others

We can raise money in our new venture firms in future, says Lupin MD

Nifty Pharma dips to 7-mth low; bears may gain control if breaks 52-wk low

Brokerages downgrade Lupin post weak Q3; see up to 17% downside

Business initiative that has a heart: Lupin eyes Lyfe beyond the pill

Lupin Digital launches Lyfe, a 24x7 monitoring ecosystem for heart patients

<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Lupin Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24100MH1983PLC029442</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>A1+</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>ICRA LIMITED</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Amit Kumar Gupta <br/> Designation: Company Secretary and Compliance Officer <br/> EmailId: akgupta@lupin.com</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Ramesh Swaminathan <br/> Designation: Executive Director Global CFO and Head of API Plus SBU <br/> EmailId: rameshswaminathan@lupin.com</div> </div> <div> <br/> Date: 07/04/2025<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>

Certificate under Reg. 74(5) of SEBI (Depositories and Participant) Regulations 2018 for the quarter ended on March 31 2025.

Lupin Healthcare (UK) Limited a wholly owned subsidiary of the Company has acquired the entire share capital of Renascience Pharma Limited United Kingdom.

Modification to the slump sale transaction of transfer of the Over-the-Counter Consumer Healthcare Business.

Transfer of Companys API R&D Division to Lupin Manufacturing Solutions Limited wholly owned subsidiary of the Company on slump sale basis.